Significant decline in the erythromycin resistance of group A streptococcus isolates at a German paediatric tertiary care centre

被引:24
作者
Farmand, S. [1 ,2 ]
Henneke, P. [1 ,2 ]
Hufnagel, M. [1 ]
Berner, R. [1 ]
机构
[1] Univ Med Ctr Freiburg, Ctr Paediat & Adolescent Med, D-79106 Freiburg, Germany
[2] Univ Med Ctr Freiburg, Ctr Chron Immunodeficiency Freiburg, D-79106 Freiburg, Germany
关键词
MACROLIDE-RESISTANCE; PYOGENES; GENE; SURVEILLANCE; ASSOCIATION; PHARYNGITIS; PREVALENCE; CHILDREN; PRTF1;
D O I
10.1007/s10096-011-1362-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Group A streptococcus (GAS) is considered to be a major pathogen of bacterial tonsillopharyngitis in children. Although GAS is generally susceptible to penicillin, macrolides are often used as the second-line treatment. Over the last several decades, the rising macrolide resistance of GAS has been detected in several countries. With the current study, we aimed to determine the development of macrolide resistance at our paediatric centre. From March 2006 to May 2009, 350 GAS isolates were tested for susceptibility to erythromycin, azithromycin, clindamycin, penicillin and cefotaxime. Macrolide-resistant isolates were screened for the presence of genes related to macrolide resistance (mefA, ermB, ermTR, prtF1). In comparison to a prior study at our hospital, the erythromycin resistance rate decreased significantly from 13.6 to 2.6%. This effect may be attributable to a more restrictive use of macrolides in children in our region.
引用
收藏
页码:707 / 710
页数:4
相关论文
共 19 条
[1]   Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients [J].
Bingen, E ;
Fitoussi, F ;
Doit, C ;
Cohen, R ;
Tanna, A ;
George, R ;
Loukil, C ;
Brahimi, N ;
Le Thomas, I ;
Deforche, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1453-1457
[2]   Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis [J].
Bisno, AL ;
Gerber, MA ;
Gwaltney, JM ;
Kaplan, EL ;
Schwartz, RH .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (02) :113-125
[3]   Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999-2000 [J].
Cantón, R ;
Loza, E ;
Morosini, MI ;
Baquero, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :9-24
[4]   Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes [J].
Clancy, J ;
Petitpas, J ;
DibHajj, F ;
Yuan, W ;
Cronan, M ;
Kamath, AV ;
Bergeron, J ;
Retsema, JA .
MOLECULAR MICROBIOLOGY, 1996, 22 (05) :867-879
[5]   Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci [J].
Facinelli, B ;
Spinaci, C ;
Magi, G ;
Giovanetti, E ;
Varaldo, PE .
LANCET, 2001, 358 (9275) :30-33
[6]   Antibiotic susceptibility in neonatal invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in Germany [J].
Fluegge, K ;
Supper, S ;
Siedler, A ;
Berner, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (11) :4444-4446
[7]   Reemergence of macrolide resistance in pharyngeal isolates of group A streptococci in Southwestern Pennsylvania [J].
Green, M ;
Martin, JM ;
Barbadora, KA ;
Beall, B ;
Wald, ER .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :473-476
[8]   Association between resistance to erythromycin and the presence of the fibronectin binding protein F1 gene, prtF1, in Streptococcus pyogenes isolates from German pediatric patients [J].
Haller, M ;
Fluegge, K ;
Jasminder, S ;
Arri, SJ ;
Adams, B ;
Berner, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :2990-2993
[9]  
Kern WV, 2008, GERMAP 2008 ANTIBIOT, P15
[10]   BACTERIAL-RESISTANCE TO MACROLIDE, LINCOSAMIDE, AND STREPTOGRAMIN ANTIBIOTICS BY TARGET MODIFICATION [J].
LECLERCQ, R ;
COURVALIN, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (07) :1267-1272